Literature DB >> 26942082

SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer.

Abhishek K Srivastava1, Esma S Yolcu2, Gunes Dinc3, Rajesh K Sharma2, Haval Shirwan4.   

Abstract

Practical experience with cancer vaccines combined with accumulated knowledge of the complex interactions between cancer and immune system rationalize the combinatorial use of immune adjuvants for better efficacy. We recently described a novel adjuvant system based on the costimulatory SA-4-1BBL and TLR4 agonist MPL that has desired therapeutic and safety profiles.

Entities:  

Keywords:  Adjuvant systems; CD137; MPL; SA-4-1BBL; TLR; cancer vaccines; lung cancer

Year:  2015        PMID： 26942082      PMCID： PMC4760279          DOI： 10.1080/2162402X.2015.1064580

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

Authors:  Jens Dannull; Zhen Su; David Rizzieri; Benjamin K Yang; Doris Coleman; Donna Yancey; Aijing Zhang; Philipp Dahm; Nelson Chao; Eli Gilboa; Johannes Vieweg
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

2.  SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.

Authors:  Abhishek K Srivastava; Gunes Dinc; Rajesh K Sharma; Esma S Yolcu; Hong Zhao; Haval Shirwan
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

3.  4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Rich-Henry Schabowsky; Abhishek K Srivastava; Kutlu G Elpek; Shravan Madireddi; Hong Zhao; Zhenping Zhong; Robert W Miller; Kathryn J Macleod; Esma S Yolcu; Haval Shirwan
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

Review 4.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

5.  Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.

Authors:  Kutlu G Elpek; Esma S Yolcu; Deanna D H Franke; Chantale Lacelle; Rich-Henry Schabowsky; Haval Shirwan
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

6.  Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.

Authors:  Rajesh K Sharma; Kutlu G Elpek; Esma S Yolcu; Rich-Henry Schabowsky; Hong Zhao; Laura Bandura-Morgan; Haval Shirwan
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

Review 7.  Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.

Authors:  Rich-Henry Schabowsky; Shravan Madireddi; Rajesh Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Curr Opin Investig Drugs       Date:  2007-12

8.  SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.

Authors:  Shravan Madireddi; Rich-Henry Schabowsky; Abhishek K Srivastava; Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

9.  Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.

Authors:  Abhishek K Srivastava; Rajesh K Sharma; Esma S Yolcu; Vahap Ulker; Kathryn MacLeod; Gunes Dinc; Haval Shirwan
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

10.  CD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.

Authors:  Rajesh K Sharma; Esma S Yolcu; Abhishek K Srivastava; Haval Shirwan
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240
  10 in total
  4 in total

Review 1.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

Review 2.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 3.  Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.

Authors:  Charles B Chesson; Andrew Zloza
Journal:  Nanomedicine (Lond)       Date:  2017-11-03       Impact factor: 5.307

4.  The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.

Authors:  Yaomei Tian; Meng Li; Chaoheng Yu; Rui Zhang; Xueyan Zhang; Rong Huang; Lian Lu; Fengjiao Yuan; Yingzi Fan; Bailing Zhou; Ke Men; Heng Xu; Li Yang
Journal:  Oncotarget       Date:  2017-07-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.